The Unexpected Risks of COVID-19 on Asthma Control in Children
Publication date: Available online 1 June 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Nicolas M. Oreskovic, T Bernard Kinane, Emmanuel Aryee, Karen A. Kuhlthau, James M. Perrin
Authors: Kim S, Jin HJ, Kim SR PMID: 32638569 [PubMed]
We report this consensus to support allergists and clinical immunologists to make optimal decisions under the urgent situation in Asia. PMID: 32638559 [PubMed]
(American College of Allergy, Asthma, and Immunology) Due to COVID-19, the 2020 ACAAI Annual Scientific Meeting will be held remotely.
THURSDAY, July 2, 2020 -- The coronavirus pandemic makes planning for July 4th a challenge this year, especially if someone in the family has allergies or asthma, an allergy expert says. " This summer will see modifications in how people celebrate...
SARS-CoV-2 has led to the COVID-19 global pandemic. Respiratory allergy and allergic asthma have not been identified as significant risk factors for COVID-19 despite their well-known association with more severe respiratory viral illnesses. Angiotensin-converting-enzyme 2 (ACE2) is the receptor for SARS-CoV-2 infections. Jackson et al (p 203), in this Letter to the Editor, aimed to determine whether respiratory allergy, allergic asthma, and/or controlled allergen exposure were associated with reductions in ACE2 gene expression, hypothesizing that this could reduce risk of COVID-19.
PMID: 32621992 [PubMed - as supplied by publisher]
Idiopathic nonhistaminergic acquired angioedema (InH-AAE) is a rare disease characterized by submucosal swelling without concomitant urticaria and poor response to antihistamines and corticosteroids.1 Compared with other forms of hereditary and acquired angioedema, InH-AAE seems to have a predilection for facial and tongue swelling, and is often difficult to diagnose as patients have normal laboratory values and no family history.1 To our knowledge, there have been no publications to date describing idiopathic nonhistaminergic angioedema as a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infe...
Publication date: Available online 17 June 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Nikolaos G. Papadopoulos, Adnan Custovic, Antoine Deschildre, Alexander G. Mathioudakis, Wanda Phipatanakul, Gary Wong, Paraskevi Xepapadaki, Ioana Agache, Leonard Bacharier, Matteo Bonini, Jose A. Castro-Rodriguez, Zhimin Chen, Timothy Craig, Francine M. Ducharme, Zeinab Awad El-Sayed, Wojciech Feleszko, Alessandro Fiocci, Luis Garcia-Marcos, James E. Gern, Anne Goh
Publication date: Available online 27 June 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Elisa Haroun-Díaz, María Vázquez de la Torre, Francisco Javier Ruano, Maria Luisa Somoza Álvarez, Diana Pérez Alzate, Paula López González, Ana Prieto-Moreno, Isabel Torres Rojas, María Desamparados Cervera García, Natalia Blanca-López, Gabriela Canto Díez
Authors: Moelling K, Broecker F Abstract Polluted air poses a significant threat to human health. Exposure to particulate matter (PM) and harmful gases contributes to cardiovascular and respiratory diseases, including allergies and obstructive lung disease. Air pollution may also be linked to cancer and reduced life expectancy. Uptake of PM has been shown to cause pathological changes in the intestinal microbiota in mice and humans. Less is known about the effects of pollution-associated microbiota on human health. Several recent studies described the microbiomes of urban and rural air samples, of the stratosphere ...